Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

Roche - Basel

Roche ends pursuit of gene sequencing company Illumina

Says chairman Franz Humer following failed $6.8bn bid

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

Jayson Dallas to lead Roche in the UK

He takes over from John Melville who has retired

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Roche invests €200m in Munich biotech centre

Creates new jobs with expansion of German diagnostic production

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links